Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib myeloprotection study in gastric or gastroesophageal junction adenocarcinoma during adjuvant and first-line chemotherapy
ChiCTR2500097520Phase 4Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trilaciclib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Shanxi Cancer Hospital. Primary endpoints: Incidence of Grade 3 neutropenia and Rate of febrile neutropenia. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500097520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097520.